{
  "docId": "019de516-de84-709f-9864-0c2e708269aa",
  "docSlug": "d2a0e3b4a50bc196c7afb3f2c93e5906",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 38 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 38,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 32,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de516-de84-709f-9864-0c2e708269aa/29",
  "deckHref": "/decks/019de516-de84-709f-9864-0c2e708269aa",
  "deckJsonHref": "/decks/019de516-de84-709f-9864-0c2e708269aa.json",
  "deckAnchorHref": "/decks/019de516-de84-709f-9864-0c2e708269aa#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.09,
        "w": 0.766,
        "x": 0.16,
        "y": 0.885
      },
      "kind": "source-note",
      "text": "1. Products with sales outside the United States impacted by F/X changes.\n2. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios.\n3. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results\nof the Vision Care segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The net\nimpact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.\n4. YTD 2022 results were not fully burdened by all stand-up costs associated with the separation",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65f4742c-74d2-425e-b19d-0c0a77523cb6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.68,
        "w": 0.905,
        "x": 0.044,
        "y": 0.17
      },
      "kind": "table",
      "text": "Bausch + Lomb\n1Q23-3Q23\n1Q22-3Q224\nReported Change\nConstant Currency Change2\nVision Care Revenue3\n$1,881M\n$1,745M\n8%\n11%\nSurgical Revenue\n$563M\n$530M\n6%\n7%\nPharmaceuticals Revenue3\n$529M\n$497M\n6%\n8%\nTotal Revenue\n$2,973M\n$2,772M\n7%\n9%\nGross Profit\n$1,632M\n$1,484M\n10%\n13%\nGross Margin\n54.9%\n53.5%\n140 bps\nR&D\n$244M\n$229M\n(7%)\n(7%)\nR&D % of Revenues\n8.2%\n8.3%\nSG&A\n$1,253M\n$1,092M\n(15%)\n(16%)\nSG&A % of Revenues\n42.1%\n39.4%\nOperating Income\n$81M\n$156M\nNet (Loss) Income Attributable to B+L\n($206M)\n$7M\nNet (Loss) Income Margin\n(6.9%)\n0.3%\nEPS Attributable to B+L\n($0.59)\n$0.02",
      "attrs": {},
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "646b4450-91fa-4c1f-bbba-48db6112d284",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.603,
        "x": 0.047,
        "y": 0.08
      },
      "kind": "title",
      "text": "YTD Total Bausch + Lomb P&L¹ (GAAP)",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b5a6459-52e9-4196-a51b-b2992587912a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}